Dupilumab leads to no or low disease activity in most moderate-to-severe atopic dermatitis patients: signs, symptoms and quality of life

被引：0
|
作者：
Blauvelt, A. [1 ]
Chen, Z. [2 ]
Hultsch, T. [3 ]
Eckert, L. [4 ]
Gadkari, A. [2 ]
Shumel, B. [2 ]
Ardeleanu, M. [2 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Regeneron Pharmaceut, Tarrytown, NY USA
[3] Sanofi Genzyme, Cambridge, MA USA
[4] Sanofi, Chilly Mazarin, France
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P079
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [31] Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis
    Bieber, Thomas
    Thyssen, Jacob P.
    Irvine, Alan D.
    Tsunemi, Yuichiro
    Chen, Yun-Fei
    Sun, Luna
    Schloebe, Andrea
    Riedl, Elisabeth
    Cork, Michael J.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (08) : 881 - 888
  • [32] Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Pink, Andrew E.
    Weidinger, Stephan
    Chan, Gary
    Lazariciu, Irina
    Clibborn, Claire
    Guler, Erman
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [33] Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
    Achten, Roselie
    Thijs, Judith
    van Luijk, Chantal
    Knol, Edward
    Delemarre, Eveline
    de Graaf, Marlies
    Bakker, Daphne
    de Boer, Joke
    van Wijk, Femke
    de Bruin-Weller, Marjolein
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02): : 239 - 243
  • [34] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
  • [35] Disease severity and needs of patients with moderate-to-severe Atopic Dermatitis
    Siegels, D.
    Abraham, S.
    Heinrich, L.
    Birkner, T.
    Haufe, E.
    Weidinger, S.
    Werfel, T.
    Schmitt, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S197 - S197
  • [36] Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score 24 or 24
    Offidani, Annamaria
    Stingeni, Luca
    Neri, Iria
    Cipriani, Filippo
    Chen, Zhen
    Rossi, Ana B.
    Lu, Yufang
    Moretti, Devis
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2022, 157 (01) : 39 - 46
  • [37] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [38] Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
    Bronova, Irina
    Berdyshev, Evgeny
    Goleva, Elena
    Danby, Simon
    Bronoff, Anna Sofia
    Richers, Brittany
    Garcia, Shannon
    Gama, Marco Ramirez
    Taylor, Patricia
    Zahn, Joseph
    Agueusop, Inoncent
    Bafna, Shantanu
    Boguniewicz, Mark
    Ong, Peck
    Zhang, Annie
    Cork, Michael
    Leung, Donald
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB5 - AB5
  • [39] Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis
    Mele-Ninot, Gemma
    Curto-Barredo, Laia
    Bonfill-Orti, Montserrat
    Exposito-Serrano, Vicente
    Munera-Campos, Monica
    Figueras Nart, Ignasi
    Riquelme-Mc Loughlin, Constanza
    Gomez-Armayones, Sara
    Spertino, Jorge
    Serra-Baldrich, Esther
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (02) : 153 - 162
  • [40] Dupilumab in Combination With JAK Inhibitor for Refractory Moderate-to-Severe Atopic Dermatitis
    Song, Xiaoting
    Liu, Bo
    Peng, Chengyue
    Tan, Yen
    Zhao, Zuotao
    DERMATOLOGIC THERAPY, 2024, 2024 (01)
12345